Clinical data | |
---|---|
Other names | RVT-602; TAK-448 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C58H80N16O14 |
Molar mass | 1225.376 g·mol−1 |
3D model (JSmol) | |
| |
|
MVT-602 (other developmental code names RVT-602, TAK-448) is a kisspeptin receptor agonist which is under development for the treatment of female infertility and hypogonadism.[1][2] It has been found to increase luteinizing hormone levels in premenopausal women.[2] As of March 2021, MVT-602 is in phase 2 clinical trials for the treatment of female infertility and hypogonadism.[1] It was also under development for the treatment of prostate cancer, but development for this indication was discontinued.[1]